Skip to main content
. 2021 Aug 10;27(20):5619–5627. doi: 10.1158/1078-0432.CCR-21-1414

Figure 2.

Figure 2. Comparative analysis of paired tissue and plasma samples in patients with advanced gastric cancer. A, Schematic depicting analyses of paired synchronous primary tissue and plasma samples in 44 patients with advanced gastric cancer. B, FGFR2 amplification status based on IHC (score), FISH (FGFR2/CEP10 ratio), and Guardant360 (pCN). Yellow boxes indicate high FGFR2 expression for tissue IHC score and FGFR2 amplification for tissue FISH or ctDNA sequencing. Low FGFR2 expression and no FGFR2 amplification are indicated by blue boxes. C, Correlations [coefficient of determination (r2)] between FGFR2 pCN and tissue CN for patients with FGFR2 amplification detected in ctDNA. D, OS based on the Kaplan–Meier method for patients with FGFR2 amplification detected in tissue+ctDNA+ versus in tissue−ctDNA+. max VAF, maximum variant allele frequency.

Comparative analysis of paired tissue and plasma samples in patients with advanced gastric cancer. A, Schematic depicting analyses of paired synchronous primary tissue and plasma samples in 44 patients with advanced gastric cancer. B, FGFR2 amplification status based on IHC (score), FISH (FGFR2/CEP10 ratio), and Guardant360 (pCN). Yellow boxes indicate high FGFR2 expression for tissue IHC score and FGFR2 amplification for tissue FISH or ctDNA sequencing. Low FGFR2 expression and no FGFR2 amplification are indicated by blue boxes. C, Correlations [coefficient of determination (r2)] between FGFR2 pCN and tissue CN for patients with FGFR2 amplification detected in ctDNA. D, OS based on the Kaplan–Meier method for patients with FGFR2 amplification detected in tissue+ctDNA+ versus in tissue−ctDNA+. max VAF, maximum variant allele frequency.